Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment

ISRCTN ISRCTN37494643
DOI https://doi.org/10.1186/ISRCTN37494643
ClinicalTrials.gov number NCT00058201
Secondary identifying numbers ESPAC-3
Submission date
01/07/2001
Registration date
01/07/2001
Last edited
28/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titlePhase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment
Study acronymESPAC-3
Study objectivesNot provided at time of registration

Please note that as of 03/09/09 the ethics and primary outcomes of this trial were updated. The end date of this trial was also extended from 01/12/2005 to 07/05/2008
Ethics approval(s)Added 03/09/09: Received from local medical ethics committee (MREC ref: 99/8/74)
Health condition(s) or problem(s) studiedPancreatic cancer
Intervention1. 5-FU and Folinic Acid: Folinic Acid D-L form: 20 mg/m2 iv bolus injection followed by 5-FU: 425 mg/m2 iv bolus injection given on 5 consecutive days every 28 days for six cycles (24 weeks)
2. Gemcitabine: 1000 mg/m2 given as iv infusion over 30 min once a week for 3 of every 4 weeks for six cycles (24 weeks)
3. No adjuvant
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)5-Fluorouracil (5FU), D-L-folinic acid, gemcitabine
Primary outcome measureAdded 03/09/09:
1. Survival at 2 and 5 years
2. Toxicity
3. Quality of life
4. Relapse free survival
Secondary outcome measuresNot provided at time of registration
Overall study start date03/07/2000
Completion date07/05/2008

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsNot provided at time of registration
Key inclusion criteria1.1. Patients who have undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas
1.2. Patients with other cancer may be included who have had complete macroscopic resection for unusual malignancies of the pancreas; cancer of the periampullary region; cancer of the intra-pancreatic bile duct; periampullary cancer of uncertain origin
2. Histological confirmation of the primary diagnosis
3. Histological examination of all resection margins
4. No evidence of malignant ascites, liver metastases, spread to other distant abdominal organs, peritoneal metastases, spread to extra-abdominal regions
5. A World Health Organisation (WHO) performance status ≤2
6. Fully recovered from surgery and fit to take part in the trial. Life expectancy of more than 3 months
7. Able to attend for administration of adjuvant therapy
8. Able to attend for long-term follow-up
9. No previous or concurrent malignancy diagnoses
10. No serious medical or psychological condition precluding adjuvant treatment
11. Fully informed written consent given
Key exclusion criteriaDoes not match inclusion criteria
Date of first enrolment03/07/2000
Date of final enrolment07/05/2008

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Phone +44 (0)207 317 5186
Email kate.law@cancer.org.uk
Website http://www.cancer.org.uk
ROR logo "ROR" https://ror.org/054225q67

Funders

Funder type

Charity

Cancer Research UK (CRUK) (UK)
Private sector organisation / Other non-profit organizations
Alternative name(s)
CR_UK, Cancer Research UK - London, CRUK
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 08/09/2010 Yes No
Results article results 11/07/2012 Yes No
Results article results 01/01/2014 Yes No
Results article results 20/02/2014 Yes No
Plain English results 28/10/2021 No Yes

Editorial Notes

28/10/2021: Cancer Research UK plain English results link added.